NADPH-Oxidase 4 (NOX4) Inhibitors as a Treatment for Idiopathic Pulmonary Disease, Fibrotic Diseases, Inflammatory Diseases, and Cancer. [PDF]
Abdel-Magid AF.
europepmc +1 more source
ABSTRACT The knockout strain collection of Saccharomyces cerevisiae has served as a valuable resource for functional genomics and yeast‐based biotechnology studies. A comprehensive single‐gene knockout strain collection, covering nearly all non‐essential genes, together with complementary mutant collections for essential genes, including temperature ...
Takashi Hirasawa
wiley +1 more source
MicroRNA-21-3p regulation of NADPH oxidase 4 and vascular endothelial growth factor A contributes to hemorrhage in cerebral cavernous malformations. [PDF]
Guo XX +5 more
europepmc +1 more source
NADPH Oxidase 4 is Not Involved in Hypoxia‐Induced Pulmonary Hypertension [PDF]
C, Veith +8 more
openaire +2 more sources
Dataset for 'Characterising NADPH oxidase in marine diatoms'
Dataset associated with the University of Southampton Doctoral Thesis 'Characterising NADPH oxidase in marine diatoms'.
Wheeler, Glen L. +3 more
core +1 more source
MicroRNA-383-5p regulation of NADPH oxidase 4 alleviates hemorrhagic transformation and improves acute outcomes after endovascular recanalization in acute ischemic stroke. [PDF]
Jiang QY +6 more
europepmc +1 more source
Mepolizumab Modifies Blood Eosinophil Proteome and Transcriptome in Severe Eosinophilic Asthma
This study investigates the effect of mepolizumab on the proteomic and transcriptomic profile of blood eosinophils in SEA patients. Mepolizumab reduces the migratory capacity and effector‐related molecular signatures of circulating eosinophils in SEA patients.
Pablo Miguéns‐Suárez +14 more
wiley +1 more source
Correction to: NADPH oxidase 4 regulates anoikis resistance of gastric cancer cells through the generation of reactive oxygen species and the induction of EGFR. [PDF]
Du S +11 more
europepmc +1 more source
NADPH oxidase-4 promotes eccentric cardiac hypertrophy in response to volume overload. [PDF]
Schnelle M +12 more
europepmc +1 more source
ABSTRACT Background Erectile dysfunction (ED) secondary to cavernous nerve injury (CNI), such as that occurring after radical prostatectomy, remains a significant clinical challenge, particularly among patients who do not respond to phosphodiesterase Type 5 inhibitors (PDE5i).
Minh Nhat Vo +6 more
wiley +1 more source

